iShares MSCI United Kingdom (FTSE) vs uniQure N.V. Ordinary Shares — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.91 (market cap $3.71B), while uniQure N.V. Ordinary Shares trades at $21.51 (market cap $1.45B). The key difference: iShares MSCI United Kingdom (FTSE) is far larger — about 2.6× uniQure N.V. Ordinary Shares's market cap, and iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI United Kingdom (FTSE) for 48 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| EWU | QURE | |
|---|---|---|
Market Cap | $3.71B | $1.45B |
Volume | 728,527 | 3,323,243 |
Sector | Broad Market / Factor | Health |
52-Week High | $49.39 | $70.59 |
52-Week Low | $41.34 | $9.03 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $707.46M |
Signals from Pluang's Aura AI — not financial advice
EWU trades at $46.82 with a modest 0.26% daily gain, though technical indicators signal bearish momentum with moving averages and overall signals pointing downward. The stock faces headwinds from UK economic concerns including rising gilt yields and inflation pressures. Recent news highlights volatility in UK markets, particularly affecting banking and housing sectors, creating a challenging environment for this UK-focused ETF.
The outlook remains cautious as rising UK borrowing costs and persistent inflation create macroeconomic headwinds. While housebuilder stocks have shown recent strength on government support programs, broader market sentiment is weighed down by energy price shocks and ECB rate hikes affecting European markets.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →